| Dennis J. Selkoe | |
|---|---|
| Photo placeholder | |
| Affiliations | Brigham and Women's Hospital Harvard Medical School |
| Country | USA |
| H-index | 250 |
| ORCID | 0000-0001-9469-1830 |
| Research Focus | Alzheimer's Disease |
| Mechanisms | Amyloid, APP processing, Synaptic plasticity |
Dennis J. Selkoe is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Dennis J. Selkoe is a leading researcher in the field of neurodegenerative diseases, affiliated with Brigham and Women's Hospital and Harvard Medical School. Their research focuses on Amyloid, APP processing, Synaptic plasticity, with particular emphasis on Alzheimer's Disease. With an h-index of 250, Selkoe is among the most cited researchers in the neuroscience field.
Selkoe's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease. Their research group has made significant contributions to the fields of Amyloid, APP processing, Synaptic plasticity, publishing in high-impact journals including Neuron, Nat Rev Neurosci.
Based at Brigham and Women's Hospital and Harvard Medical School, Selkoe collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.
John Hardy, Reisa A. Sperling, David M. Holtzman, Michael S. Wolfe
The study of Dennis J. Selkoe has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Page auto-generated from NeuroWiki researcher database. Last updated: 2026-02-26.
Dennis J. Selkoe is the Vincent and Stella Coates Professor of Neurologic Diseases at Harvard Medical School and Director of the Center for Neurologic Diseases at Brigham and Women's Hospital. He is a preeminent researcher in Alzheimer's disease and other neurodegenerative disorders, with seminal contributions to understanding amyloid biology and protein aggregation.
Dr. Selkoe's research has been foundational to the amyloid hypothesis and our understanding of Alzheimer's disease pathogenesis. His work demonstrated that amyloid-beta is continuously produced and cleared in the normal brain, and that an imbalance between production and clearance leads to accumulation in Alzheimer's disease.
His discovery that soluble, oligomeric forms of amyloid-beta are the primary toxic species has profoundly influenced therapeutic development strategies, shifting focus from plaque removal to preventing oligomer formation.
Dennis J. Selkoe is the Vincent and Stella Coates Professor of Neurologic Diseases at Harvard Medical School and Director of the Center for Neurologic Diseases at Brigham and Women's Hospital. He is a preeminent researcher in Alzheimer's disease and other neurodegenerative disorders, with seminal contributions to understanding amyloid biology and protein aggregation.
Dr. Selkoe's research has been foundational to the amyloid hypothesis and our understanding of Alzheimer's disease pathogenesis. His work demonstrated that amyloid-beta is continuously produced and cleared in the normal brain, and that an imbalance between production and clearance leads to accumulation in Alzheimer's disease.
His discovery that soluble, oligomeric forms of amyloid-beta are the primary toxic species has profoundly influenced therapeutic development strategies, shifting focus from plaque removal to preventing oligomer formation.
Dennis J. Selkoe is the Vincent and Stella Coates Professor of Neurologic Diseases at Harvard Medical School and Director of the Center for Neurologic Diseases at Brigham and Women's Hospital. He is a preeminent researcher in Alzheimer's disease and other neurodegenerative disorders, with seminal contributions to understanding amyloid biology and protein aggregation.
Dr. Selkoe's research has been foundational to the amyloid hypothesis and our understanding of Alzheimer's disease pathogenesis. His work demonstrated that amyloid-beta is continuously produced and cleared in the normal brain, and that an imbalance between production and clearance leads to accumulation in Alzheimer's disease.
His discovery that soluble, oligomeric forms of amyloid-beta are the primary toxic species has profoundly influenced therapeutic development strategies, shifting focus from plaque removal to preventing oligomer formation.
Dr. Selkoe has published over 500 papers on amyloid and Alzheimer's disease, including:
His work established the central role of amyloid in Alzheimer's disease.
Dr. Selkoe's research has shaped therapeutic development by:
Dr. Selkoe is a member of the National Academy of Sciences and has received the Breakthrough Prize, the Potamkin Prize, and other major awards.